02.19.15
Amin Talati, one of the foremost dietary supplement and pharmaceutical law practices under the direction of Rakesh Amin and Ashish Talati for the past 10 years, is now Amin Talati & Upadhye with the addition of its newest member, Shashank Upadhye. Based in Chicago, Amin Talati & Upadhye is a full-service regulatory and intellectual property firm helping clients safely navigate the minefield of U.S. food, drug, dietary supplement, cosmetic and medical device regulations, while assisting in the development, commercialization, protection and enforcement of intellectual property.
Mr. Upadhye, who will oversee areas relating to drugapproval, drug marketing, supply chain management, marketing and data exclusivity issue, has extensive experience with legal and regulatory matters in the pharmaceutical and medical device industries. He joins the practice from an international AmLaw 100 group where he headed the life sciences/FDA department. Prior to that, Mr. Upadhye worked at Apotex, Inc., in Toronto, Ontario, where he was the vice president global head of intellectual property. Prior to Apotex, he was held the same positionfor Sandoz, Inc. in Princeton, NJ and Eon Labs, Inc. in Long Island, NY.
As the former head of intellectual property at three leading pharmaceutical companies, Mr. Upadhye interacted with all levels of technical and business management and counseled in matters such as product selection, research and development support, FDA regulatory affairs, litigation management, and product launch management. As a senior member of the executive team, he routinely advised and coordinated legal efforts regarding global litigation in patent, trademark, and copyrights and counseled generic drug clients regarding early market opportunities in the field of “Paragraph IV” brand-generic pharmaceutical matters. His specialties include development of strategy and tactics in abbreviated new drug application matters, patent opinion work on infringement and freedom to operate and patent litigation in the drug and medical device spaces.
Mr. Upadhye is also the author of the industry's leading book, entitled "Generic Pharmaceutical Patent and FDA Law", a book that helps clients navigate the legal regimes in patent and FDA law. In addition, he is the author of many articles and presenter of topics that have helped shape the pharmaceutical industry.
“Our attorneys have extensive experience dealing with federal regulatory, intellectual property, litigation and transactional matters,” said Mr. Amin. “We immerse ourselves in the industries we service and remain abreast of the latest developments in federal regulations and intellectual property law.”
Amin Talati & Upadhye employs proven regulatory experts, skilled patent and trademark attorneys, as well as proven litigators and trial attorneys. The firm said it is committed to providing value-added strategic counseling and solutions to a variety of federal regulatory and intellectual property matters.
Visit the website at www.AminTalati.com for more information.
Mr. Upadhye, who will oversee areas relating to drugapproval, drug marketing, supply chain management, marketing and data exclusivity issue, has extensive experience with legal and regulatory matters in the pharmaceutical and medical device industries. He joins the practice from an international AmLaw 100 group where he headed the life sciences/FDA department. Prior to that, Mr. Upadhye worked at Apotex, Inc., in Toronto, Ontario, where he was the vice president global head of intellectual property. Prior to Apotex, he was held the same positionfor Sandoz, Inc. in Princeton, NJ and Eon Labs, Inc. in Long Island, NY.
As the former head of intellectual property at three leading pharmaceutical companies, Mr. Upadhye interacted with all levels of technical and business management and counseled in matters such as product selection, research and development support, FDA regulatory affairs, litigation management, and product launch management. As a senior member of the executive team, he routinely advised and coordinated legal efforts regarding global litigation in patent, trademark, and copyrights and counseled generic drug clients regarding early market opportunities in the field of “Paragraph IV” brand-generic pharmaceutical matters. His specialties include development of strategy and tactics in abbreviated new drug application matters, patent opinion work on infringement and freedom to operate and patent litigation in the drug and medical device spaces.
Mr. Upadhye is also the author of the industry's leading book, entitled "Generic Pharmaceutical Patent and FDA Law", a book that helps clients navigate the legal regimes in patent and FDA law. In addition, he is the author of many articles and presenter of topics that have helped shape the pharmaceutical industry.
“Our attorneys have extensive experience dealing with federal regulatory, intellectual property, litigation and transactional matters,” said Mr. Amin. “We immerse ourselves in the industries we service and remain abreast of the latest developments in federal regulations and intellectual property law.”
Amin Talati & Upadhye employs proven regulatory experts, skilled patent and trademark attorneys, as well as proven litigators and trial attorneys. The firm said it is committed to providing value-added strategic counseling and solutions to a variety of federal regulatory and intellectual property matters.
Visit the website at www.AminTalati.com for more information.
